Patents by Inventor John Copland
John Copland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11833144Abstract: A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II): or a pharmaceutically acceptable salt thereof; wherein: R1 is halo; X is —(C?O)NR4—; Y is ?and R2, R3, and R4 are each independently H or an unsubstituted alkyl.Type: GrantFiled: August 24, 2021Date of Patent: December 5, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Hu Zeng
-
Publication number: 20230310419Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: January 26, 2023Publication date: October 5, 2023Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20230201192Abstract: This document relates to methods and materials involved in assessing and/or treating mammals (e.g., humans) having cancer (e.g., a SCD1-associated cancer). For example, methods for determining whether or not a cancer is likely to be responsive to one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors (e.g., a selective SCD1 inhibitor (SSI)) are provided. In some cases, the methods and materials for treating a mammal by administering, to the mammal, one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to one or more SCD1 polypeptide inhibitors e.g., SSI-4) are provided.Type: ApplicationFiled: June 16, 2021Publication date: June 29, 2023Inventors: John A. Copland, III, Laura Ann Marlow
-
Patent number: 11596629Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: GrantFiled: February 28, 2018Date of Patent: March 7, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Kim
-
Publication number: 20220411389Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: April 5, 2022Publication date: December 29, 2022Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 11325892Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: May 24, 2019Date of Patent: May 10, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20220062259Abstract: This document provides methods and materials for treating mammals (e.g., humans) having an autoimmune disease (e.g., a systemic autoimmune disease such as lupus). For example, one or more SCD1 polypeptide inhibitors (e.g., a SSI) can be administered to a mammal having an autoimmune disease (e.g., lupus) to treat the mammal.Type: ApplicationFiled: August 24, 2021Publication date: March 3, 2022Inventors: John A. Copland, III, Hu Zeng
-
Patent number: 11243207Abstract: This document relates to methods and materials for identifying and/or treating mammals having cancer (e.g., a SCD1-associated cancer). For example, methods and materials for using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors to treat a mammal having cancer (e.g., a SCD1-associated cancer) are provided.Type: GrantFiled: March 28, 2019Date of Patent: February 8, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow
-
Publication number: 20210147813Abstract: Disclosed are cell culture scaffolds comprising a scaffold composition comprising chitosan and alginate, hyaluronic acid, or chondroitin sulfate, wherein the scaffold is formed from an aqueous solution comprising greater than 4 wt % chitosan. These scaffolds can be contacted with cells, e.g., patient-derived cancer cells. The scaffolds provide 3D structure allowing appropriate cell function to occur. A scaffold of chitosan and chondroitin sulfate are also disclosed. Scaffold compositions comprising chitosan and alginate, hyaluronic acid, or chondroitin sulfate are also disclosed. Methods of making these scaffolds, e.g., by freeze casting or 3D printing, and using them to evaluate a patient's cancer cell and personalize treatment are also disclosed.Type: ApplicationFiled: April 3, 2019Publication date: May 20, 2021Inventors: Stephen J. FLORCZYK, Kailei XU, Zi WANG, Ratna CHAKRABARTI, John COPLAND
-
Publication number: 20200061055Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: February 28, 2018Publication date: February 27, 2020Applicant: Mayo Foundation for Medical Education and ResearchInventors: Christina Von Roemeling, Han W. Tun, John A. Copland, III, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20190345123Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: May 24, 2019Publication date: November 14, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20190302121Abstract: This document relates to methods and materials for identifying and/or treating mammals having cancer (e.g., a SCD1-associated cancer). For example, methods and materials for using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors to treat a mammal having cancer (e.g., a SCD1-associated cancer) are provided.Type: ApplicationFiled: March 28, 2019Publication date: October 3, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow
-
Patent number: 10301273Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: August 7, 2015Date of Patent: May 28, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 10160972Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: August 31, 2017Date of Patent: December 25, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Patent number: 9970253Abstract: A downhole tool mechanism for applying a driving force, such as a cutter tool for cutting a line captured within the tool, comprises a resiliently compressible member for storing a compressive force; a retaining device for maintaining storage of the compressive force until released; a trigger mechanism for releasing the compressive force when the trigger mechanism is activated. In one form the resiliently compressible member comprises a plurality of concentrically arranged spring washers each having a radial slot therein for receiving a line along the length of the resiliently compressible member. In the cutter form, there is a cutter arranged to cut the line when the trigger mechanism is activated, and the trigger mechanism is activated when the tool receives a shock force to one or both ends.Type: GrantFiled: October 26, 2012Date of Patent: May 15, 2018Assignee: PEAK WELL SYSTEMS PTY LTDInventor: David John Copland Manson
-
Publication number: 20170362595Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20170226073Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: August 7, 2015Publication date: August 10, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20160152986Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: December 7, 2015Publication date: June 2, 2016Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Patent number: 9233102Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: March 7, 2013Date of Patent: January 12, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20150045418Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: March 7, 2013Publication date: February 12, 2015Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling